Value of Chest Ultrasonography in ILD Screening

Role od Chest Ultrasonography in Interstitial Lung Diseases

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06260930

Enrollment

Registered

2024-02-15

Start date

2017-01-31

Completion date

2019-12-31

Last updated

2024-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease

Brief summary

The main aim of this study is to detect the value of transthoracic ultrasonography in the diagnosis and assessment of ILDs in correlation to chest X- ray, blood gases, pulmonary function test and echocardiography and to compare it with high resolution CT (HRCT) as a golden diagnostic investigation.

Detailed description

Interstitial lung disease (ILD) refers to a group of disorders that are characterized by varying combinations of inflammation and fibrosis involving the space between the epithelial and endothelial basement membranes.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Inclusion criteria

* Adults (≥18 years) diagnosed with ILD * All patients must fulfil the 2018 criteria for HRCT chest finding for the diagnosis of Usual interstitial pneumonia (UIP) form

Exclusion criteria

* Patients with cardiac diseases (Left-sided Heart failure, pulmonary edema) \[they may have findings of multiple B lines on transthoracic ultrasound examination which mimic ILD findings\]. * Patients with chronic kidney diseases (as patients presented with nephrogenic pulmonary edema may have findings of multiple B lines on transthoracic ultrasound examination which mimic ILD findings).

Design outcomes

Primary

Measure	Time frame	Description
Sensitivity and specificity of the lung sonography for interstitial lung disease screening	12 months	To estimate the sensitivity and specificity of the lung sonography for interstitial disease screening in comparison with HRCT. \[Time Frame: 12 months\]

Outcome results